# Spyre Therapeutics, Inc. (SYRE) stock news and updates

As of November 4, 2026. Source: https://www.clearthesis.ai/updates/SYRE

## Our view on the Spyre Therapeutics, Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/SYRE

## Latest updates on Spyre Therapeutics, Inc.

### Mixed results as bowel disease trials succeed but joint disease drug is halted

*November 3, 2026 · earnings · significance: major · signal: neutral*

Spyre shared a split update alongside its quarterly results. Its lead drug for inflammatory bowel disease, SPY003, showed positive early data, meaning all three of its main bowel disease treatments have now passed the initial test to show they work as intended. The company is now moving faster than planned to test these drugs in combination, with results expected by late 2027. However, the company will stop developing SPY072 for rheumatic diseases like rheumatoid arthritis and psoriatic arthritis. While the drug was safe, it did not show a large enough benefit to justify moving forward. This narrows the company's focus back toward its core bowel disease pipeline. Spyre ended the quarter with a loss of $0.94 per share, slightly wider than the $0.79 loss analysts expected, but it remains well-funded with over $400 million in new cash raised.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000132/0001636282-26-000132-index.htm)

### Spyre raised about 350 million dollars in a new stock sale

*November 3, 2026 · filing · significance: notable · signal: positive*

On October 5, Spyre entered an agreement to sell roughly 4.1 million shares of common stock at $85.00 per share. This sale is expected to bring in about $350 million in gross proceeds before fees. For a biotech company with no revenue, these cash raises are the lifeblood of the business. Spyre plans to use the money to keep its clinical trials running, prepare for the final phase of testing, and start manufacturing its drug candidates. While selling new shares dilutes current owners by giving them a smaller piece of the company, it provides the necessary runway to reach the next round of trial results without running out of cash.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1636282/000162828026065291/0001628280-26-065291-index.htm)

## Spyre Therapeutics, Inc. earnings

In Q3 2026, reported on November 3, 2026, Spyre Therapeutics, Inc. posted earnings of $-0.94 per share against $-0.79 expected.

## Recent analyst activity on SYRE

- October 19, 2026: BTIG Kept rating at Buy.
- October 11, 2026: UBS Set target. Price target: $120.00.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/SYRE
